Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials
Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor
ziritaxestat in patients with IPF. Design, Setting, and Participants The 2 identically designed,
phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa,
Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26
countries). A total of 1306 patients with IPF were randomized (525 patients at 106 sites in …
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor
ziritaxestat in patients with IPF. Design, Setting, and Participants The 2 identically designed,
phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa,
Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26
countries). A total of 1306 patients with IPF were randomized (525 patients at 106 sites in …